Chimeric, Mutated, Or Recombined Hybrid (e.g., Bifunctional, Bispecific, Rodent-human Chimeric, Single Chain, Rfv, Immunoglobulin Fusion Protein, Etc.) Patents (Class 530/387.3)
  • Patent number: 11027016
    Abstract: Disclosed is a pharmaceutical preparation comprising a CD147 monoclonal antibody, a buffer, a protein protectant and a surfactant. The pharmaceutical preparation can maintain the stability of the CD147 monoclonal antibody over a long period of time. Also disclosed are the use of the pharmaceutical preparation in the preparation of a drug for treating CD147-related diseases, in particular non-small cell lung cancer, and a method for preparing the pharmaceutical preparation.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: June 8, 2021
    Inventor: Xiaochun Chen
  • Patent number: 11027030
    Abstract: The present invention relates to a kit for radiolabelling a targeting agent with gallium-68. The present invention also relates to the use of the kit for radiolabelling a targeting agent, and a method for radiolabelling a targeting agent with gallium-68 using the kit.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: June 8, 2021
    Assignee: ANMI S.A.
    Inventors: Ludovic Wouters, Geoffroy Kaisin, André Luxen, Marc Léonard, Samuel Voccia
  • Patent number: 11021544
    Abstract: The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: June 1, 2021
    Assignee: Ablynx N.V.
    Inventors: Carlo Boutton, Daniel Janssen, Peter Casteels, Peter Schotte, Francis Descamps
  • Patent number: 11021530
    Abstract: The present invention relates to the field of biotechnology, and in particular to the field of antibodies. Provided herein are novel methods for removing glycosylated antibody variants from an antibody preparation, an antibody preparation obtained by said method, and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: June 1, 2021
    Assignee: Hexal AG
    Inventors: Claudia Torella, Benjamin Hackner, Carsten Funke, Michael Otten, Christina Hildebrandt, Renate Lafuntal, Florian Wolschin
  • Patent number: 11001611
    Abstract: The present disclosure relates to relates methods and associated compositions that provide fast, efficient site-selective conjugation of a protein, such as the pore-forming protein ?-hemolysin, to a biomolecule, such as a DNA polymerase, and the use of such site-selective protein-biomolecule conjugates in nanopore devices and methods.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: May 11, 2021
    Assignee: Roche Sequencing Solutions, Inc.
    Inventors: Dmitriy Gremyachinskiy, Christos Tzitzilonis
  • Patent number: 10988537
    Abstract: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: April 27, 2021
    Assignee: Regeneren Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Eric Smith, Supriya Patel
  • Patent number: 10982008
    Abstract: The invention provides for a domain-exchanged antibody comprising a light chain (LC) composed of VL-CH3, and a heavy chain (HC) comprising VH-CH3-CH2-CH3, wherein the VL-CH3 of the LC is dimerising with the VH-CH3 of the HC thereby forming a domain-exchanged LC/HC dimer comprising a CH3LC/CH3HC domain pair, and means and method for producing the same.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: April 20, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Gordana Wozniak-Knopp, Sylvia Dietrich, Florian Rüker, Alec Gross, Stefan Becker
  • Patent number: 10982221
    Abstract: The present invention describes the plant-based production of a therapeutic anti-virus antibody.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: April 20, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Qiang Chen, Huafang Lai, Jonathan Hurtado
  • Patent number: 10973904
    Abstract: The present invention relates to immunogenic immune complexes, related compositions, and related methods.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: April 13, 2021
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Taia Wang, Jad Mamaary
  • Patent number: 10947268
    Abstract: In some embodiments, the present invention provides a method of purifying a protein of interest with a reduced level of aggregation formation in cation exchange (CEX) chromatography, comprising: (a) providing a mixture comprising the protein of interest and one or more contaminants; (b) loading the mixture onto a CEX resin coupled with arginine; and (c) eluting the protein of interest from the resin, thereby purifying the protein of interest with a reduced level of aggregation formation in CEX chromatography.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: March 16, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Zhengjian Li, Xuankuo Xu, Chao Huang, Zhiqiang Chen
  • Patent number: 10941382
    Abstract: The present invention provides: a platelet production promoter that contains one or more substances selected from the group consisting of Wnt inhibitors and FMS-like tyrosine kinase (FLT) inhibitors; and a platelet production method that uses this platelet production promoter.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: March 9, 2021
    Assignees: Kyoto University, Megakaryon Corporation
    Inventors: Koji Eto, Hideya Seo, Akira Ota, Yukitaka Ito, Yasuko Hazama
  • Patent number: 10942178
    Abstract: A device detects a target molecule in a sample in a sample container to measure the target molecule. A first particle is functionalized with a first binding molecule capable of specifically binding to said target molecule. A surface structure includes a second binding molecule. The surface structure covers a flat sensor or is present on a second particle. The first particle is capable of binding the second binding molecule of the surface structure directly or indirectly. The first and/or second binding molecule is indirectly attached to the particle surface of the first and/or second particle and/or the flat sensor surface via a long and rigid linker molecule. A length and a consistency of the linker molecule is selected such as to result in an average extension length of the linker of more than 60 nm. A number of particle clusters or of bound particles is directly or inversely related to an amount of the target molecules present in the sample.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: March 9, 2021
    Assignee: Koninklijke Philips N.V.
    Inventors: Toon Hendrik Evers, Maatje Koets
  • Patent number: 10941205
    Abstract: Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: March 9, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Harald Duerr, Sebastian Fenn, Ulrich Goepfert, Sabine Imhof-Jung, Christian Klein, Laurent Lariviere, Michael Molhoj, Joerg Thomas Regula, Petra Rueger, Wolfgang Schaefer
  • Patent number: 10934355
    Abstract: Aspects of the present disclosure include methods of treating a subject to reduce adhesion formation, the method comprising administering to a subject in need of thereof an agent that that targets adhesion-formation by injured mesothelial cells. The agent can act at a variety of checkpoints in the development of adhesions by injured mesothelial cells, including: targeting the injured mesothelial cells for destruction, recruiting inflammatory macrophages to the site of adhesion, preventing neutrophil recruitment to the site of adhesion, and/or inhibiting the expression or activity of a gene product whose expression is induced in the injured mesothelial cells. Compositions and kits for performing the methods are also provided.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: March 2, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jonathan Tsai, Nathaniel Fernhoff, Rahul Sinha, Yuval Rinkevich, Irving L. Weissman
  • Patent number: 10919977
    Abstract: A bispecific tetravalent antibody comprising an IgG having a pair of heavy chains and a pair of light chains, and two scFv components being connected to either C or N terminals of the heavy or light chains. The bispecific tetravalent antibody may have a binding specificity for two different members of EGFR family.
    Type: Grant
    Filed: December 19, 2015
    Date of Patent: February 16, 2021
    Assignees: SYSTIMMUNE, INC., Sichuan Baili Pharmaceutical Co. Ltd.
    Inventors: Zeren Gao, Phil Tan, Brian R. Kovacevich, Blair R. Renshaw, Jeffrey B. Adamo, Nga Sze Amanda Mak, Shi Zhuo, Lan Chen, Yi Zhu
  • Patent number: 10912842
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD123 and conjugates thereof.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: February 9, 2021
    Assignee: Seattle Genetics, Inc.
    Inventors: May Kung Sutherland, Lori Westendorf, Django Sussman
  • Patent number: 10913803
    Abstract: The present invention is directed to novel heterodimeric antibodies.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: February 9, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Chu, Rumana Rashid, Umesh Muchhal, Sung-Hyung Lee
  • Patent number: 10894821
    Abstract: The invention relates generally to activatable antibodies and methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 19, 2021
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Henry Bernard Lowman, Shouchun Liu
  • Patent number: 10822426
    Abstract: Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73. The humanized antibodies are useful for the treatment of cancer. Further provided are nucleic acids encoding humanized 1E9 antibodies and methods of inhibiting cell proliferation using the humanized antibodies provided herein.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: November 3, 2020
    Assignees: CORVUS PHARMACEUTICALS, INC., BIOATLA, LLC
    Inventors: Emily Piccione Griffin, Richard A. Miller, Gerhard Johann Frey, Hwai Wen Chang
  • Patent number: 10823733
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: November 3, 2020
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura
  • Patent number: 10793853
    Abstract: The present invention relates a targeted delivery system for siRNA or antisense technology. In one embodiment, the invention provides for a method of treating cancer by administering a therapeutically effective dosage of HerPBK10 combined with siRNA, resulting in the inhibition of Her2 expression and cell death. In another embodiment, a plurality of HerPBK10 combined with siRNA form a nanoparticle.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: October 6, 2020
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventor: Lali K. Medina-Kauwe
  • Patent number: 10792370
    Abstract: The present invention relates to an antibody-drug conjugate, in particular, to an antibody-drug conjugate targeting an epidermal growth factor receptor. The present invention also relates to a composition comprising the antibody-drug conjugate, and use of the antibody-drug conjugate in manufacture of a medicament for the prophylaxis and/or treatment of a disease associated with epidermal growth factor receptor, in particular in manufacture of a medicament for prophylaxis and/or treatment of colon cancer, rectal cancer, head and neck cancer, lung cancer, ovarian cancer, cervical cancer, bladder cancer and esophageal cancer. The antibody-drug conjugate of the invention has a good inhibition activity on tumor cell growth both in vivo and in vitro, and has low toxicity, and thus has a good application prospect.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: October 6, 2020
    Assignee: SHANGHAI MIRACOGEN INC
    Inventor: Chaohong Hu
  • Patent number: 10781268
    Abstract: A method for decreasing the immunogenicity of antibody variable domains is disclosed.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: September 22, 2020
    Assignee: Novartis AG
    Inventors: David Urech, Leonardo Borras
  • Patent number: 10774135
    Abstract: The present disclosure provides fully human variant anti-AIP2 variant antibodies, and antigen binding proteins thereof, having improved characteristics compared to the wild type anti-AIP2 antibody E7 from which the variant clones are derived. The variant anti-AIP2 antibodies exhibit improved binding to AIP1 and AIP4 as determined in an in vitro quorum sensing reporter assay, have improved thermal stability, provided complete protection against infection with two different strains of Staphylococcus aureus MRSA in pre-treated mice, and can be manufactured at higher yields.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: September 15, 2020
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanliang Zhang, Gunnar F. Kaufmann
  • Patent number: 10766949
    Abstract: The present invention relates to a method for preparing a whole bovine-derived broadly neutralizing antibody against serotype O foot-and-mouth disease virus, and belongs to the technical field of antibody preparation. The method includes the following steps: 1) conducting the immunization on the cattle; 2) screening for the serotype O foot-and-mouth disease virus antigen-specific single B cells; 3) amplifying variable region genes of the heavy and light chains; 4) acquiring constant region sequences of the heavy and light chains; 5) preparing a full-length heavy chain vector; 6) co-transfecting a cell, taking the supernatant of cell culture, and purifying. The method utilizes different foot-and-mouth disease virus strains to infect cattle and obtains a neutralizing antibody capable of neutralizing three topotypes of serotype O FMDVs by screening, and thus can obtain a whole bovine-derived broadly neutralizing monoclonal antibody.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: September 8, 2020
    Assignee: Lanzhour Veterinary Research Institute, Chinese Academy of Agricultural Sciences
    Inventors: Kun Li, Zengjun Lu, Zaixin Liu, Yimei Cao, Huifang Bao, Yingli Chen, Sheng Wang, Pinghua Li, Pu Sun, Xingwen Bai, Dong Li
  • Patent number: 10738130
    Abstract: Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human and MUC16 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human and monkey MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: August 11, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lauric Haber, Eric Smith, Marcus Kelly, Jessica R. Kirshner, Sandra Coetzee, Alison Crawford, Thomas Nittoli, Yashu Liu
  • Patent number: 10675352
    Abstract: Extracellular drug conjugates (EDCs) targeting CD38 are useful in the treatment of diseases such as cancer and immune disorders, including asthma.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: June 9, 2020
    Assignee: Centrose, LLC
    Inventor: James R. Prudent
  • Patent number: 10669337
    Abstract: The invention relates generally to antibodies, activatable antibodies, multispecific antibodies, and multispecific activatable antibodies that specifically bind to at least CD3, as well as to methods of making and using these antibodies, activatable antibodies, multispecific antibodies, and/or multispecific activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: June 2, 2020
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Bryan Allen Irving, Sherry Lynn La Porte, Jason Gary Sagert, Daniel Robert Hostetter, Olivia Jennifer Razo, Clayton William White, Jennifer Hope Richardson
  • Patent number: 10640562
    Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: May 5, 2020
    Assignee: MCMASTER UNIVERSITY
    Inventors: Jonathan Lorne Bramson, Christopher W. Helsen, Joanne Alicia Hammill, Kenneth Anthony Mwawasi
  • Patent number: 10603303
    Abstract: The invention provides methods of treating or preventing an ocular disease or disorder in a subject, methods of treating or preventing ocular pain or discomfort comprising, administering to the subject a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a transient receptor potential melastatin 8 (TRPM8) antagonist. In certain preferred embodiments, the ocular disease or disorder is a dry eye disease.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: March 31, 2020
    Assignee: Ora, Inc.
    Inventors: Mark B. Abelson, Peter Corcoran, Keith Lane
  • Patent number: 10577418
    Abstract: The present application is directed to an invention based on the discovery that the BLCA-38 antibody is actually an antibody population comprising two distinct monoclonal antibodies. The claims define an isolated antibody population comprising first antibodies and/or antigen binding fragments thereof defined by specific heavy chain and light chain variable regions and wherein the antibody population does not contain second antibodies defined by specific light chain variable regions. The claims also define hybridoma cells, cultures capable of producing such antibody populations, compositions comprising such antibody populations, nucleic acid molecules encoding such antibodies, vectors, host cells thereof, and processes for production of the antibody populations of the invention.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: March 3, 2020
    Assignee: Minomic International LTD.
    Inventors: Douglas Campbell, Irene Justiniano Fuenmayor, Aline Nocon, Julie Soon, Quach Truong, Bradley Walsh, Sandra Wissmueller
  • Patent number: 10570208
    Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-? and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: February 25, 2020
    Assignee: Baylor Research Institute
    Inventors: Yong-Jun Liu, Sandra Zurawski, SangKon Oh, Shino Hanabuchi, Haruyuki Fujita, Hideki Ueno, Patrick Blanco, Hyemee Joo
  • Patent number: 10570196
    Abstract: The disclosure provides methods of treating tauopathies (e.g. Alzheimer's disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia with Parkinsonism linked to chromosome 17, Pick's Disease, Progressive Supranuclear Palsy, Dementia Pugilistica, Down's Syndrome and others) by administering humanized antibodies. The disclosure also provides the anti-tau humanized antibodies that bind the N-terminal region of tau and also bind to pathological tau aggregates, conformational epitopes and peptides mimicking these epitopes (mimotopes).
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: February 25, 2020
    Inventor: Anahit Ghochikyan
  • Patent number: 10556942
    Abstract: The present invention relates to the purification of TNFR:Fc fusion protein. More specifically related to process of purification of TNFR:Fc fusion protein wherein the HCP is reduced. The present invention is directed to the use of mixed-mode chromatography and/or affinity chromatography to produce TNFR:Fc fusion protein which is substantially free of at least one of the protein degrading enzyme present in HCP.
    Type: Grant
    Filed: June 13, 2015
    Date of Patent: February 11, 2020
    Assignee: LUPIN LIMITED
    Inventors: Abir Banerjee, Chandranath Ganapathy, Sorab Rustom Mody, Ashok Mishra
  • Patent number: 10525130
    Abstract: The present invention provides stable pharmaceutical antibody formulations, including liquid drug product formulations and lyophilized drug product formulations, comprising an IgG4 binding agent and a citrate buffer, wherein the pH of the formulation is at or below both pH 6 and the pI of the binding agent. The formulations can be used in the treatment of chronic bowel diseases or rheumatoid arthritis.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: January 7, 2020
    Assignee: Sanofi
    Inventors: Julia Schnieders, Dirk Usener, Sabrina Ruggeberg, Ahmed Youssef, Martina Kirsch, Annika Hagendorf
  • Patent number: 10526397
    Abstract: The invention provides modifications within human or humanized single domain antibody fragments (sdAbs) that prevent recognition by pre-existing antibodies, to isolated polypeptides that include these modifications, and to methods and uses thereof.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: January 7, 2020
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Quinn Deveraux
  • Patent number: 10519247
    Abstract: The disclosure provides monoclonal bispecific antibodies targeting HER2 and HER3. The disclosure also provides monospecific tetravalent HER3 antigen binding antibodies. Still further provided by the disclosure are methods of treating a cancer in a subject, comprising administering to the subject a therapeutically effective amount of an antibody provided by the disclosure.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: December 31, 2019
    Assignee: Board of Regents,The University of Texas System
    Inventors: E. Sally Ward, Raimund Ober, Jeffrey Kang, Jayakumar Poovassery
  • Patent number: 10517929
    Abstract: Provided herein are pharmaceutical compositions, formulations and dosage forms comprising variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). Methods of using the pharmaceutical compositions, formulations and dosage forms are also provided herein.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: December 31, 2019
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Darrin Anthony Lindhout, Charles V. Olson
  • Patent number: 10501558
    Abstract: Provided herein are modified Fc proteins comprising non-natural amino acid residues at site-specific positions, conjugates of the modified Fc proteins for therapy or diagnosis, compositions comprising the modified Fc proteins and conjugates thereof, methods of their production and methods of their use. The modified Fc proteins and conjugates are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: December 10, 2019
    Assignee: Sutro Biopharma, Inc.
    Inventors: Christopher D. Thanos, Leslie McEvoy, Gang Yin, Kalyani Penta, Ramesh Baliga, Sunil Bajad, Sonia Pollitt, Chris Murray, Alex Steiner, Avinash Gill
  • Patent number: 10494440
    Abstract: Provided herein are methods for promoting neurogenesis in neural tissue of a patient exhibiting at least one symptom of a central nervous system disorder, the method comprising administering to a subject in need thereof an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D).
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 3, 2019
    Assignee: Vaccinex, Inc.
    Inventors: Ernest S. Smith, Maurice Zauderer
  • Patent number: 10494599
    Abstract: The invention is comprised within automated devices for cell culture. The invention relates to a cell culture method and system which allows modifying in a controlled manner the density and the number of cells in a culture. Specifically, the present invention relates to an iterative method the number of iteration steps of which is modified depending on the demand for the density and the number of cells necessary for the culture duration.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: December 3, 2019
    Assignee: ALGARIS CELL S.L.
    Inventors: David Horna Tomas, Miguel Costa Ferrando
  • Patent number: 10487156
    Abstract: The present invention relates to multispecific antibodies, for example bispecific antibodies, and methods for the isolation or purification of the same. The antibodies of the invention comprise first and second heavy chain-light chain pairings wherein each pairing comprises a distinct selective recognition site including one or more amino acid residues contributed from the heavy chain and the light chain of the pairing. The first and second selective recognition sites differ by at least one amino acid residue and can be differentially bound by first and second selective recognition agents according to the methods of the invention. Such methods facilitate the production of antibody preparations enriched for multispecific antibodies having the correct functional heavy chain-light chain pairings.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: November 26, 2019
    Assignee: argenx BVBA
    Inventors: Christophe Frederic Jerome Blanchetot, Johannes Joseph Wilhelmus De Haard
  • Patent number: 10487151
    Abstract: Disclosed herein are methods and compositions related to antibody fragments which specifically bind sialyl-Tn epitope of tumor-associated glycoprotein 72 (TAG-72).
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: November 26, 2019
    Assignee: Ohio State Innovation Foundation
    Inventors: Thomas J. Magliery, Brandon J. Sullivan, Nicholas E. Long
  • Patent number: 10471099
    Abstract: Methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express a sortaggable surface protein, which allows for surface modification in the presence of a sortase. Also described herein are surface modified enucleated red blood cells, e.g., conjugated with an agent of interest such as a peptide, a detectable label, or a chemotherapeutic agent, and uses thereof in delivering the agent to a subject.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: November 12, 2019
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Harvey Lodish, Hidde L. Ploegh, Hsiang-Ying Lee, Jiahai Shi, Lenka Hoffman, Novalia Pishesha
  • Patent number: 10457749
    Abstract: The invention relates to the purification of bispecific antibodies carrying a different specificity for each binding site of the immunoglobulin molecule from a mixture of monospecific antibodies. The bispecific antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain. This invention in particular relates to the isolation of these bispecific antibodies from mixtures that contain monospecific antibodies having two Kappa light chains or portions thereof and monospecific antibodies having two Lambda light chains or portions thereof. The invention also provides the methods of efficiently purifying these bispecific antibodies.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: October 29, 2019
    Assignee: NovImmune SA
    Inventors: Nicolas Fouque, Jean François Depoisier, Keith Wilson, Judith Vajda, Egbert Müller, Romain Dabre
  • Patent number: 10457748
    Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I): (Vxx)nVx-Cx-X-V1; and b) a polypeptide chain of formula (II): (Vyy)nVy-Cy c) a polypeptide of formula (III): V2 wherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, V2 represents a variable domain, n independently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V and V2, in particular where a disulphide bond is present.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: October 29, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Emma Dave, Sam Philip Heywood, David Paul Humphreys
  • Patent number: 10392438
    Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: August 27, 2019
    Assignee: PFIZER INC.
    Inventors: Eric M. Bennett, Nathan Higginson-Scott, Lioudmila Tchistiakova, Kimberly A. Marquette, Janet E. Paulsen, Ruth E. Gimeno
  • Patent number: 10377833
    Abstract: The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies. The present invention also relates to Chinese Hamster ovary (CHO) mutant cell line that has a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: August 13, 2019
    Assignee: Beijing Mabworks Biotech Co., Ltd.
    Inventors: Feng Li, Boyan Zhang, Pei Ye, Jian Zhao, Sijia Huang, Chunyang Jin
  • Patent number: 10357571
    Abstract: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: July 23, 2019
    Assignees: Thomas Jefferson University, City of Hope
    Inventors: John C. Williams, Cindy Zer, Kendra N. Avery, Ulrich Rodeck, Joshua M. Donaldson, Csaba Kari
  • Patent number: RE48370
    Abstract: The present invention provides a method of measuring the levels of BCMA in a biological sample, specifically upon the B cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE, and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with BLyS antagonists, either singly or in combination with other immune suppressive drugs.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: December 29, 2020
    Assignees: ZYMOGENETICS, INC., UNIVERSITY OF WASHINGTON
    Inventors: Stacey R. Dillon, Jane A. Gross, Keith B. Elkon